EL-PFDD Meeting for Wilson Disease:Patients and Caregivers Make Their Voices Heard

The WDA organized and led a daylong “Externally-Led Patient-Focused Drug Development” (EL-PFDD) meeting on January 29, 2026, designed to inform the FDA and other key stakeholders, including drug developers and healthcare providers, about the challenges facing patients living with Wilson disease (WD), their caregivers, and their families.